Document is current
Any future updates will be listed below
-
Authors
Schreiber, Stefan https://orcid.org/0000-0003-2254-7771
Waetzig, Georg H.
Laudes, Matthias
Rosenstiel, Philip https://orcid.org/0000-0002-9692-8828
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EXC 2167 (Excellence Cluster PMI), EXC 2167 (Excellence Cluster PMI), EXC 2167 (Excellence Cluster PMI), EXC 2167 (Excellence Cluster PMI))
- License Information
-
More Information
Article History
Received: 15 March 2024
Accepted: 30 July 2024
First Online: 5 September 2024
Competing interests
: S.S. reports indirect stock ownership in Gerion Biotech as well as consulting and personal fees from AbbVie, Allergosan, Amgen, Arena, BMS, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Galapagos/Gilead, HIKMA, I-Mab, Janssen, Lilly, Morphic, MSD, Mylan, Pfizer, Prometheus, Protagonist, Provention Bio, Sandoz/Hexal, Takeda and Theravance. G.H.W. is in part-time employment by CONARIS Research Institute AG (Kiel, Germany). M.L. reports lecture fees from Amarin, AstraZeneca, Boehringer Ingelheim, Chiesi, HRA Pharma, Lilly, Novo Nordisk, Roche and Sanofi. P.R. reports stock ownership in Gerion Biotech and consulting fees from Takeda.
